ECYT - Endocyte, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.93
+0.43 (+2.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.50
Open16.50
Bid13.30 x 1400
Ask23.00 x 800
Day's Range16.50 - 17.04
52 Week Range1.17 - 17.70
Volume618,788
Avg. Volume1,332,385
Market Cap1.177B
Beta0.04
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateMay 7, 2018 - May 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.67
Trade prices are not sourced from all markets
  • The 4 Best Biotech Stocks of 2018 (So Far)
    Motley Fool4 days ago

    The 4 Best Biotech Stocks of 2018 (So Far)

    Find out what's pushing shares of these biotechs through the roof.

  • 3 Huge Biotech Winners in 2018 (So Far)
    Motley Fool7 days ago

    3 Huge Biotech Winners in 2018 (So Far)

    Why these stocks are the best biotech performers so far this year.

  • GlobeNewswire9 days ago

    Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177

    Endocyte, Inc. (ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group of companies, announced today that ITM´s subsidiary, Isotope Technologies Garching GmbH (ITG), and Endocyte have signed a long-term global supply agreement for the highly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta® to support clinical and commercial supply of 177Lu-PSMA-617, through 2035. “We are pleased to secure this long-term strategic partnership to ensure a reliable supply of no-carrier-added Lutetium-177 through commercialization,” said Mike Sherman, president and CEO of Endocyte. Under the terms of the supply agreement, ITG will provide Endocyte with 100% of the Lutetium-177 required for the phase 3 VISION trial.

  • 4 Biotech Stocks That Tripled in the First Half of 2018
    Motley Fool16 days ago

    4 Biotech Stocks That Tripled in the First Half of 2018

    Find out how six drugmakers tripled their shareholders' money in six short months.

  • The 3 Best Biotech Stocks of 2018 So Far
    Motley Fool20 days ago

    The 3 Best Biotech Stocks of 2018 So Far

    Can these sizzling-hot biotechs keep the momentum going?

  • MarketWatch21 days ago

    Harry Boxer’s four momentum stocks breaking out

    Here are four stocks in biotech, energy and media that are breaking out on news. Endocyte Inc.(ECYT) had a strong session Tuesday, up 81 cents, or 6%, to $14.45 on 1.4 million shares traded. The biopharmaceutical company, which on Monday was added to the Russell 3000 Index, announced that an image from its Phase 2 prostate cancer study was selected as “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.

  • GlobeNewswire21 days ago

    Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that an image from a Phase 2 study of 177Lu-PSMA-617, led by Dr. Michael Hofman of the Peter McCallum Cancer Centre in Melbourne, Australia, was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the “Image of the Year.” The image depicts the positron emissions tomography (PET) scans of eight patients before treatment with 177Lu-PSMA-617 and at three months following treatment. “This recognition reflects the potential of 177Lu-PSMA-617 and radioligand therapies to be a new treatment modality for patients with metastatic castration-resistant prostate cancer (mCRPC).” said Mike Sherman president and CEO of Endocyte.

  • GlobeNewswire23 days ago

    Endocyte to Join the Russell 3000® Index

    WEST LAFAYETTE, Ind., June 25, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected ...

  • GlobeNewswire26 days ago

    Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

    WEST LAFAYETTE, Ind., June 22, 2018-- Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple presentations related ...

  • 3 Soaring Biotech Stocks. Can They Keep Climbing?
    Motley Fool27 days ago

    3 Soaring Biotech Stocks. Can They Keep Climbing?

    Find out if these big gainers have any more fuel in the tank.

  • Endocyte (ECYT) Up 5.1% Since Earnings Report: Can It Continue?
    Zackslast month

    Endocyte (ECYT) Up 5.1% Since Earnings Report: Can It Continue?

    Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswirelast month

    Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Center in Omaha, NE, a member of Precision Cancer Research.   The international, prospective, open-label, multicenter, randomized phase 3 study is evaluating patients with progressive prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have received at least one novel androgen axis drug (abiraterone or enzalutamide) and at least one taxane regimen. “We are pleased to announce the initiation of this important clinical trial so quickly following our end-of-phase 2 meeting with the FDA.

  • MarketWatch2 months ago

    Harry Boxer’s five momentum stocks to watch, including Canopy Growth and Impinj

    A range of momentum stocks in biotech, technology and the cannabis industry have charts that are showing strength. Akcea Therapeutics Inc.(AKCA) rose $1.56, or 6.7%, to $24.85 Tuesday on volume of 336,400 shares, slightly below normal but the best in six sessions. The biopharmaceutical company announced it will present at the Jefferies Global Healthcare Conference on June 5.

  • GlobeNewswire2 months ago

    Endocyte to Present at Jefferies Healthcare Conference

    A live audio webcast of the Company's presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company's website for 90 days following the conference. Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section.

  • Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
    Motley Fool2 months ago

    Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)

    The meeting hasn't even started, and stocks are already moving.

  • ACCESSWIRE2 months ago

    Blog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MAC

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Insmed Inc. (NASDAQ: INSM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INSM as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).

  • Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop?
    Simply Wall St.2 months ago

    Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Endocyte Inc’s (NASDAQ:ECYT) track record on a high level, to giveRead More...

  • GlobeNewswire2 months ago

    Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that a poster with data from the Peter MacCallum Cancer Centre will be presented on Endocyte’s lead investigational therapy at the 2018 ASCO Annual Meeting on Saturday, June 2, 2018. Updated data from the phase 2 study of 177Lu-PSMA-617 as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC), including data from an additional 20 patient expansion cohort, will be highlighted by the poster. “We are very pleased that we continue to see high rates of PSA response, even in heavily pre-treated patients,” said Mike Sherman, president and CEO of Endocyte.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ECYT earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Endocyte Inc Earnings Call

  • Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
    Zacks2 months ago

    Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

    Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

  • MarketWatch2 months ago

    Four momentum stocks to watch amid earnings reports

    In focus: Arrowhead Pharmaceuticals, Endocyte, Legacy Reserves and Impinj.

  • Endocyte (ECYT) Posts Narrower than Expected Loss in Q1
    Zacks2 months ago

    Endocyte (ECYT) Posts Narrower than Expected Loss in Q1

    Endocyte???s first-quarter 2018 loss was narrower-than-expected.

  • Associated Press2 months ago

    Endocyte: 1Q Earnings Snapshot

    The West Lafayette, Indiana-based company said it had a loss of 16 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...